RBC Capital analyst Shagun Singh lowered the firm’s price target on Edwards Lifesciences to $82 from $86 but keeps an Outperform rating on the shares. The company’s Q3 results were in-line, but its TAVR business was much in focus ahead of the quarter, which missed expectations despite posting double-digit ex-fx sales growth in U.S. and internationally, the analyst tells investors in a research note. Edwards Lifesciences’ Q4 guidance now implies FY23 guide to be at the low-end of the range for both sales and EPS, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences price target lowered to $80 from $100 at TD Cowen
- Edwards Lifesciences price target lowered to $68 from $83 at Piper Sandler
- Edwards Lifesciences price target lowered to $84 from $100 at JPMorgan
- Edwards Lifesciences price target lowered to $75 from $91 at Baird
- Edwards Lifesciences price target lowered to $85 from $90 at Mizuho
Questions or Comments about the article? Write to editor@tipranks.com